Ameritas Investment Partners’s Adamas Pharmaceuticals ADMS Stock Holding History

Ameritas Investment Partners’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,883	Closed	-$5K	–	3186
2020 Q1	$5K	Hold	1,883	–	–	﹤0.01%	2845
2019 Q4	$7K	Hold	1,883	–	–	﹤0.01%	2863
2019 Q3	$10K	Hold	1,883	–	–	﹤0.01%	2769
2019 Q2	$12K	Hold	1,883	–	–	﹤0.01%	2747
2019 Q1	$13K	Hold	1,883	–	–	﹤0.01%	2617
2018 Q4	$16K	Hold	1,883	–	–	﹤0.01%	2476
2018 Q3	$38K	Hold	1,883	–	–	﹤0.01%	2147
2018 Q2	$49K	Buy	1,883 +582	+45%	+$16.1K	﹤0.01%	2001
2018 Q1	$31K	Hold	1,301	–	–	﹤0.01%	2196
2017 Q4	$44K	Hold	1,301	–	–	﹤0.01%	1999
2017 Q3	$27K	Hold	1,301	–	–	﹤0.01%	2262
2017 Q2	$23K	Hold	1,301	–	–	﹤0.01%	2383
2017 Q1	$23K	Buy	+1,301	New	+$22.2K	﹤0.01%	2340

Other funds holding ADMS

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Ameritas Investment Partners's ADMS Position: Q2 2020 in Review

Ameritas Investment Partners sold out of Adamas Pharmaceuticals (ADMS) in Q2 2020, closing a stake of 1,883 shares — an estimated $5K sold.

Ameritas Investment Partners first reported a position in ADMS in Q1 2017 and held it in 13 quarters. The position peaked at $49K in Q2 2018. 61 funds tracked by Wall St. Rank hold ADMS as of Q2 2020.

Ameritas Investment Partners reported no remaining Adamas Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Ameritas Investment Partners sold 1,883 Adamas Pharmaceuticals shares in Q2 2020, an estimated $5K.
Ameritas Investment Partners first reported a position in Adamas Pharmaceuticals in Q1 2017 and held it in 13 quarters.
Ameritas Investment Partners's Adamas Pharmaceuticals position peaked at $49K in Q2 2018.
61 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2020.

Based on Ameritas Investment Partners's 13F filing for Q2 2020, filed 5 Aug 2020.